Recent Press Releases

European Commission Grants Marketing Authorization for Gilead's Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

European Commission Grants Marketing Authorization for Gilead's Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma -- First-in-Class Oral Treatment...

FDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes

- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise

CYRAMZA™ In Combination With Paclitaxel Significantly Improves Overall Survival In Second-Line Gastric Cancer Patients

-- Phase III RAINBOW Trial Data Published in The Lancet Oncology --

INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Eli Lil

VIVUS AND AUXILIUM ANNOUNCE FDA APPROVAL OF STENDRA SNDA; STENDRA NOW FIRST AND ONLY ORAL ERECTILE DYSFUNCTION TREATMENT APPROVED TO BE TAKEN APPROXIMATELY 15 MINUTES BEFORE SEXUAL ACTIVITY

VIVUS AND AUXILIUM ANNOUNCE FDA APPROVAL OF STENDRA SNDA; STENDRA NOW FIRST AND ONLY ORAL ERECTILE DYSFUNCTION TREATMENT APPROVED TO BE TAKEN APPROXIMATELY 15 MINUTES BEFORE SEXUAL ACTIVITY MOUNTAIN...

CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies

CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies WOONSOCKET, R.I., Sept. 17, 2014 /PRNewswire/ -- An analysis done by the CVS Health Research Institute...

Bayer plans to focus entirely on Life Science businesses

Concentration on HealthCare and CropScience / MaterialScience to be floated on the stock market by 2016 at the latest / Planned separation to benefit both Bayer and MaterialScience / Employment...

Salix Secures Additional Intellectual Property Relating to Rifaximin

Salix Secures Additional Intellectual Property Relating to Rifaximin RALEIGH, N.C.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Cipla Limited has granted Salix...

EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema

EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema Regeneron plans to submit sBLA for this indication by...

Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock

- Endo's Proposal Provides Auxilium Shareholders with Substantial Premium, Immediate Cash Value, and Ongoing Participation in Endo's Global Expansion - Combination would Accelerate Endo's...

AUXILIUM RESPONDS TO UNSOLICITED PROPOSAL FROM ENDO INTERNATIONAL

Adopts One Year Stockholder Rights Plan CHESTERBROOK, Pa., Sept. 17, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today confirmed that...

Abbott Included In Top 10 Best Companies by Working Mother Magazine

Moms Value Paid Parental Leave and Flexible Work Arrangements as Abbott Is Recognized for the Fourteenth Consecutive Year

ABBOTT PARK, Ill.,

"UNVEIL" Survey Reveals a Life Interrupted by Lupus

Results Show How Disease Takes a Toll on Life for People With Lupus and Lupus Caregivers

WASHINGTON, Sept.

ACCU-CHEK® Aviva Expert, the first and only stand-alone blood glucose meter system with a built-in insulin calculator, is now available

ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice

Takeda Announces Reorganization to Propel Continued Growth

Osaka, Japan, September, 16th, 2014 – Takeda Pharmaceutical Company Limited ("Takeda") today announced plans to redesign its global organizational structure to realize its goal of...

Health Canada approves Yervoy® (ipilimumab) for first-line treatment of adults with metastatic melanoma, the most deadly form of skin cancer

Health Canada approves Yervoy® (ipilimumab) for first-line treatment of adults with metastatic melanoma, the most deadly form of skin cancer Immunotherapy treatment with long-term survival in...

Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study

Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study Ingelheim, Germany and Indianapolis, US, 16 September, 2014...

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device used in the heart that functions like a stent but dissolves over time

ABB

Expert Briefing on Health Care Sector Stocks - Edwards Lifesciences, Catamaran, Quest Diagnostics, Aetna, and WellPoint

Editor Note: For more information about this release, please scroll to bottom.

LONDON, September 15, 2014